Literature DB >> 19633367

Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients.

A Peggy Graveland1, Michiel de Maaker, Boudewijn J M Braakhuis, Remco de Bree, Simone E J Eerenstein, Elisabeth Bloemena, C René Leemans, Ruud H Brakenhoff.   

Abstract

A great disappointment in head and neck cancer surgery is that 10-30% of head and neck squamous cell carcinoma (HNSCC) patients develop local recurrences despite histopathologically tumor-free surgical margins. These recurrences result from either minimal residual cancer (MRC) or preneoplastic lesions that remain behind after tumor resection. Distinguishing MRC from preneoplasic lesions is important to tailor postoperative radiotherapy more adequately. Here we investigated the suitability of quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) using human Ly-6D (hLy-6D) transcripts as molecular marker to detect MRC in surgical margins. Submucosal samples of deep surgical margins were collected from 18 non-cancer control patients and 67 HNSCC patients of whom eight had tumor-positive surgical margins. The samples were analyzed with hLy-6D qRT-PCR, and the data were analyzed in relation to the clinicohistological parameters. A significant difference was shown between the group of patients with histopathological tumor-positive surgical margins and the non-cancer control group (p<0.001), and the group of patients with histopathological tumor-free surgical margins (p=0.001). This study shows a novel approach for molecular analysis of deep surgical margins in head and neck cancer surgery. The preliminary data of this approach for detection of MRC in deep margins of HNSCC patients are promising.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19633367      PMCID: PMC4619043          DOI: 10.3233/CLO-2009-0474

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  3 in total

1.  Molecular diagnosis of minimal residual disease in head and neck cancer patients.

Authors:  A Peggy Graveland; Boudewijn J M Braakhuis; Simone E J Eerenstein; Remco de Bree; Elisabeth Bloemena; Michiel de Maaker; Michiel W M van den Brekel; Frederike Dijk; Wilma E Mesker; Hans J Tanke; C Rene Leemans; Ruud H Brakenhoff
Journal:  Cell Oncol (Dordr)       Date:  2012-09-04       Impact factor: 6.730

2.  The utility of molecular diagnostics to predict recurrence of head and neck carcinoma.

Authors:  C Pena Murillo; X Huang; A Hills; M McGurk; A Lyons; J-P Jeannon; E Odell; A Brown; K Lavery; W Barrett; M Sherriff; R Brakenhoff; M Partridge
Journal:  Br J Cancer       Date:  2012-08-23       Impact factor: 7.640

3.  Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma.

Authors:  Clara Backes; Henning Bier; Andreas Knopf
Journal:  Oncotarget       Date:  2017-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.